BEVERLY, MA–(Marketwired – May 26, 2016) Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis.
As disclosed on May 24, 2016, the trial enrolled 115 patients with mild to moderate plaque psoriasis, graded at a score of 2 (“mild”) or 3 (“moderate”) on the 5-point Investigator’s Global Assessment (IGA) scale. The IGA scale ranges from a score of 0 (“clear”) to a score of 4 (“severe”). The 12-week trial was structured with four arms, three receiving different dosing regimens of oral Prurisol (50mg, 100mg, 200mg) and one placebo arm. The primary endpoint was a 2-point reduction in the IGA score at Day 84.
Complete details of the Prurisol trial can be found at:
New Information: Greatest Efficacy Seen in Patients with Moderate Psoriasis
As previously released, the trial achieved its primary endpoint in patients treated with 200mg of oral Prurisol. Among patients participating in the study with the severest form of psoriasis, those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46.2% of patients who received Prurisol 200mg. This data was derived from analyses of all patients randomized across all 9 participating study sites.
Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time.
In light of Prurisol’s greater efficacy in treating moderate psoriasis cases, the Company expects the next clinical trial of Prurisol will target patients with moderate to severe psoriasis, with an optimal dosing regimen continuing to be assessed.
Prurisol Offers Psoriasis Sufferers a Potential New Treatment
Cellceutix is extremely proud of the Phase 2 Prurisol results. Simply put, the drug’s efficacy compares favorably with many current and various types of treatments for psoriasis (see the study linked to below), including apremilast or Otezla®, which is the leading oral FDA approved anti-psoriasis drug. It is interesting to do a side-by-side comparison between the two based on publicly available literature, and it could be argued that Prurisol performs on par with, if not better than, Otezla® at the identical stage of development
Leo Ehrlich, Cellceutix Chief Executive Officer, commented: “Until now, Prurisol has largely been an unknown compound among many in the national psoriasis community. The completed Phase 2 study, with its compelling results, is starting to change that. We are now eager to advance Prurisol into its next FDA trial, for moderate to severe psoriasis, where we believe the drug may show even greater efficacy in treating this debilitating condition that affects millions of people. Should Prurisol go on to gain FDA approval, psoriasis sufferers, the world over, would stand to benefit greatly.”
Prurisol is a small molecule that acts through immune modulation and PRINS reduction. In laboratory studies, Prurisol was found to be effective against psoriasis in animal models, both in induced psoriasis and in a xenograft model using human psoriatic tissue. Prurisol eliminated virtually all signs of psoriasis with no reoccurrence of the lesions. Prurisol is synthesized through a five-step process using commercially available starting materials.
About Prurisol’s 505(b)(2) Pathway
Under the FDA’s 505(b)(2) regulatory pathway, a drug’s road to market approval can be significantly shortened and at much reduced costs. Often only one pivotal Phase 3 study, enrolling a smaller number of patients than is typical, may be required. For more information about the FDA’s 505(b)(2) program, please visit: